197 related articles for article (PubMed ID: 23405851)
1. The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes.
Oh TJ; Kim MY; Shin JY; Lee JC; Kim S; Park KS; Cho YM
Clin Endocrinol (Oxf); 2014 Feb; 80(2):221-7. PubMed ID: 23405851
[TBL] [Abstract][Full Text] [Related]
2. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
3. Incretin secretion in obese Korean children and adolescents with newly diagnosed type 2 diabetes.
Park SH; Jung MH; Cho WK; Park MS; Suh BK
Clin Endocrinol (Oxf); 2016 Jan; 84(1):72-9. PubMed ID: 25903996
[TBL] [Abstract][Full Text] [Related]
4. Impact of incretin on early-phase insulin secretion and glucose excursion.
Shen J; Chen Z; Chen C; Zhu X; Han Y
Endocrine; 2013 Oct; 44(2):403-10. PubMed ID: 23283820
[TBL] [Abstract][Full Text] [Related]
5. Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release.
de Jesús Garduno-Garcia J; Gastaldelli A; DeFronzo RA; Lertwattanarak R; Holst JJ; Musi N
J Clin Endocrinol Metab; 2018 Jul; 103(7):2613-2619. PubMed ID: 29672742
[TBL] [Abstract][Full Text] [Related]
6. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
[TBL] [Abstract][Full Text] [Related]
7. Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic.
Tura A; Muscelli E; Gastaldelli A; Ferrannini E; Mari A
Diabetologia; 2014 Jun; 57(6):1199-203. PubMed ID: 24658843
[TBL] [Abstract][Full Text] [Related]
8. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
9. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
[TBL] [Abstract][Full Text] [Related]
10. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
[TBL] [Abstract][Full Text] [Related]
11. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
12. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.
Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B
Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768
[TBL] [Abstract][Full Text] [Related]
13. The incretin effect does not differ in trained and untrained, young, healthy men.
Lund MT; Dalby S; Hartmann B; Helge J; Holst JJ; Dela F
Acta Physiol (Oxf); 2014 Mar; 210(3):565-72. PubMed ID: 24354574
[TBL] [Abstract][Full Text] [Related]
14. Impaired incretin secretion and pancreatic dysfunction with older age and diabetes.
Geloneze B; de Oliveira Mda S; Vasques AC; Novaes FS; Pareja JC; Tambascia MA
Metabolism; 2014 Jul; 63(7):922-9. PubMed ID: 24854384
[TBL] [Abstract][Full Text] [Related]
15. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes.
Lee S; Yabe D; Nohtomi K; Takada M; Morita R; Seino Y; Hirano T
Endocr J; 2010; 57(2):119-26. PubMed ID: 19881250
[TBL] [Abstract][Full Text] [Related]
16. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
17. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.
Gjesing AP; Ekstrøm CT; Eiberg H; Urhammer SA; Holst JJ; Pedersen O; Hansen T
Diabetologia; 2012 May; 55(5):1338-45. PubMed ID: 22349073
[TBL] [Abstract][Full Text] [Related]
18. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
Greenfield JR; Farooqi IS; Keogh JM; Henning E; Habib AM; Blackwood A; Reimann F; Holst JJ; Gribble FM
Am J Clin Nutr; 2009 Jan; 89(1):106-113. PubMed ID: 19056578
[TBL] [Abstract][Full Text] [Related]
19. Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus.
Bonde L; Vilsbøll T; Nielsen T; Bagger JI; Svare JA; Holst JJ; Larsen S; Knop FK
Diabetes Obes Metab; 2013 Aug; 15(8):713-20. PubMed ID: 23406269
[TBL] [Abstract][Full Text] [Related]
20. Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes.
Grespan E; Giorgino T; Natali A; Ferrannini E; Mari A
Metabolism; 2021 Jan; 114():154415. PubMed ID: 33137379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
